Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial (Q36489752)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ilan Goldenberg

4

object named as

Ilan Goldenberg

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Yaron Arbel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Robert Klempfner

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sagit Benzekry

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Nir Shlomo

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Enrique Z Fisman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Alexander Tenenbaum

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

BIP Study Group

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

0 references

publication date

22 January 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Cardiovascular Diabetology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

https://scigraph.springernature.com/pub.10.1186/s12933-016-0332-6

0 references

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Triglycerides and cardiovascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Residual macrovascular risk in 2013: what have we learned?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

The controversies of statin therapy: weighing the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Drug treatment of lipid disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

30 September 2017

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Bezafibrate treatment is associated with a reduced rate of re-hospitalization in smokers after acute coronary syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Combination lipid therapy in type 2 diabetes

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

https://api.crossref.org/works/10.1186%2FS12933-016-0332-6

21 January 2018

Ipact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4722704

21 September 2018

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation of metabolic syndrome with long-term mortality in acute and stable coronary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The remnants of residual risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/26794137

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12933-016-0332-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26794137%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36489752&oldid=1528515878"